Rahul Ballal, PhD

Rahul is a biotech executive with more than 15 years of experience in building companies, business development, and company financing. Rahul previously served as Imara’s (IMRA) president and chief executive officer from Series A, through an IPO, raising $200MM in capital and completing a merger with Enliven Therapeutics (ELVN) . Prior to this role at Imara, he served as chief business officer of Northern Biologics and as an entrepreneur-in-residence at Versant Ventures. Previously, Rahul was vice president of business development at Flexion Therapeutics (FLXN) and an associate at ASM ventures. Additionally, Rahul serves on the Board of Directors of Agios Pharmaceuticals (AGIO), Enliven Therapeutics (ELVN) and Vaderis Therapeutics AG. Rahul holds a Ph.D. in biochemistry from Georgetown University, an MS in bioinformatics from Johns Hopkins University and a BS in biology from Brown University.

CEO, Mediar Therapeutics


Join our email list to receive exclusive offers

Opt In